Trial Profile
Assessment and Prognostic Significance of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements During Regadenoson Stress Cardiac Magnetic Resonance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- 22 Oct 2019 Status changed from recruiting to completed.
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
- 10 Mar 2016 New trial record